U.S. markets open in 6 hours 24 minutes
  • S&P Futures

    3,732.00
    +41.75 (+1.13%)
     
  • Dow Futures

    29,827.00
    +289.00 (+0.98%)
     
  • Nasdaq Futures

    11,443.50
    +157.75 (+1.40%)
     
  • Russell 2000 Futures

    1,739.00
    +24.10 (+1.41%)
     
  • Crude Oil

    84.02
    +0.39 (+0.47%)
     
  • Gold

    1,714.80
    +12.80 (+0.75%)
     
  • Silver

    21.07
    +0.48 (+2.31%)
     
  • EUR/USD

    0.9877
    +0.0049 (+0.50%)
     
  • 10-Yr Bond

    3.6510
    0.0000 (0.00%)
     
  • Vix

    30.10
    -1.52 (-4.81%)
     
  • GBP/USD

    1.1374
    +0.0055 (+0.49%)
     
  • USD/JPY

    144.7470
    +0.1270 (+0.09%)
     
  • BTC-USD

    19,845.19
    +650.87 (+3.39%)
     
  • CMC Crypto 200

    450.66
    +15.31 (+3.52%)
     
  • FTSE 100

    6,908.76
    0.00 (0.00%)
     
  • Nikkei 225

    26,992.21
    +776.42 (+2.96%)
     

Can-Fite BioPharma's Namodenoson Improves Liver Function, Long Term Data Shows

·1 min read
  • Can-Fite BioPharma (NYSE: CANFreports new data from Phase 2 trial evaluating namodenoson in advanced liver cancer, including the overall survival of nearly four years in two patients under treatment.

  • Additional findings show the disappearance of ascites (abnormal buildup of fluid in the abdomen), normal liver function, and good quality of life.

  • In one patient, stable disease was recorded with the disappearance of peritoneal carcinomatosis (late-stage manifestation of several gastrointestinal malignancies).

  • Namodenoson continues to demonstrate a favorable safety profile and is well tolerated with no severe adverse events reported.

  • The company concluded End-of-Phase 2 meetings with the FDA and European Medicines Agency. Both agencies agreed with Can-Fite's proposed pivotal Phase 3 trial design of Namodenoson to treat patients with advanced hepatocellular carcinoma (HCC), with underlying Child-Pugh B7 cirrhosis.

  • The company can conduct one pivotal trial with 450 subjects for registration in both the U.S. and European markets.

  • Namodenoson has Orphan Drug Designation for HCC in the U.S. and Europe, has Fast Track Status in the U.S., and is currently treating liver cancer patients through a compassionate use program in Israel.

  • Price Action: CANF gained 31.9% at $3.10 in premarket trading on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.